Updates

lobal Health Limited Date: July 30, 2026 Ref:- GHL/2026-27/EXCH/34 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Code: 543654 Symbol: MEDANTA Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) Dear Sir(s), We would like to inform you that the Board of Directors of Global Health Limited (‘GHL/Company’) at its meeting held today i.e. Thursday, July 30, 2026, has inter alia, approved the following: 1. Unaudited Standalone and Consolidated Financial Results of the Company for the First Quarter ended June 30, 2026 (‘Financial Results’). The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as Exhibit-I pursuant to Regulation 33 of the Listing Regulations. 2. Notice of 22nd Annual General Meeting (AGM) of the Company to be held on Wednesday, September 16, 2026 at 12:00 Noon through Video Conferencing/Other Audio Video Means (‘VC/OAVM’) Facility. 3. Pursuant to Regulation 42 of Listing Regulations, has fixed the record date for the purpose of determining entitlement of the shareholders for the payment of final dividend for the financial year 2025-26, which shall be paid to the shareholders within 30 days from the date of declaration, if declared by the shareholders at the 22nd AGM. Symbol Type of Security Record date for Purpose payment of dividend NSE: MEDANTA Equity Friday, August 14, 2026 Payment of final dividend of BSE: 543654 Rs. 0.50/- per equity share for the financial year 2025-26, subject to approval of the shareholders at the ensuing AGM. Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 Limited 4. Appointment of Mr. Pradeep Kumar Singh designated as ‘Chief Digital Officer’ and one of the SMPs of the Company, basis the recommendation of Nomination and Remuneration Committee w.e.f. July 30, 2026. The details as required under Regulation 30 are enclosed as Annexure-II. 5. Approved the revised construction plan of Company’s upcoming hospital at Guwahati thereby increasing the proposed bed capacity from 400 beds to 650 beds. The details as required under Regulation 30 are enclosed as Annexure-III (in substitution of our earlier intimations in this regard dated April 28, 2025 and October 25, 2025). The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges. The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 03:25 P.M. Thanking You, For Global Health Limited Rahul Ranjan Company Secretary & Compliance Officer M. No. A17035 Encl: a/a Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 Walker Chandiok &_Co LLP Welk r Chandlok I CCI UP 21st Floor, DLF Square Jacaranda Marg, IJlF Phase 11 Gurugram • 122 002 India T t91124 462 8089 F ·HU 124 462 800 Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Global Health Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') which includes GHL Employee Welfare Trust ('the Trust') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Chartered AocoJn1an1s Walke< Chandiok & Co LLP is registered wnh l1rrwted l1ab1l1ty with 1dentlficatJai Off,ces m Ahmedabad. Benga,luru. Chandigarh. Chenna1. Oehradun. Goa. Gurugram. Hyderabad. lndcre, K<x::hl, Kolkata. Mumbai, number AAC..2065 and has ns registered New Odh1 NOide and Pune office at L-41, Connaug'H Cirrus. Outer Cirde, New Delli, 110001,lndia Walker Chandiok &_Co LLP Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 ~ ," w'' ~ I I -L cW>-NOto,t ~ r~«□) ,,' o Tarun Gupta 1 . i:= Partner :j Membership No. 507892 ~ $; UDIN: 26507892SZSYTl9786 ~EbA~" Place: Gurugram Date: 30 July 2026 Chartered Accountants Global Health Limited Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi-110024, India Corporate Office: Medan ta - The Medicit)', Sector- 38, Gurgaon, Haryana -122001, India CIN:L8S110DL2004PLCl28319 Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org Statement of standalone unaudited financial results for the quarter ended 30 June 2026 (fin millions unless otherwise stated) Quarter ended Year ended S No. Particulars 30 June 2026 31 March 2026 30 June 202S 31 March 2026 Unaudited Refer note 8 Unaudited Audited Income I Revenue from operations 10,787.23 9,606.29 8,821.56 37,093.78 II Other income 240.60 358.05 231.39 1,064.08 Total income ll,027.83 9,964.34 9,052.95 38,157.86 Ill Expenses Cost of materials consumed 2,261.59 1,886.44 1,921.63 7,858.56 Purchases of stock-in-trade - (0.05) 25.59 19.43 Changes in inventories of stock-in-trade - - 39.61 46.11 Employee benefits expense 2,854.73 2,556.81 2,329.45 9,892.59 Finance costs 158.90 134.64 56.58 410.85 Depreciation and amortisation expense 546.04 522.08 334.08 1,709.07 Reta [Showing first 8,000 characters — download PDF for full document]